When.com Web Search

  1. Ad

    related to: eptinezumab jjmr vyepti

Search results

  1. Results From The WOW.Com Content Network
  2. Eptinezumab - Wikipedia

    en.wikipedia.org/wiki/Eptinezumab

    Eptinezumab was approved for medical use in the United States in February 2020. [9] [10]In November 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization for the medicinal product Vyepti, intended for the prophylaxis of migraine. [7]

  3. Calcitonin gene-related peptide receptor antagonist - Wikipedia

    en.wikipedia.org/wiki/Calcitonin_gene-related...

    As of February 2020, eptinezumab (Vyepti) was approved by the FDA for the treatment of migraine via intravenous infusion as well. [26] Three small-molecule antagonists have been approved for treatment of migraine: ubrogepant, rimegepant, and atogepant. [4] [3] [5] Ubrogepant and rimegepant are approved for acute treatment.

  4. Calcitonin gene-related peptide - Wikipedia

    en.wikipedia.org/wiki/Calcitonin_gene-related...

    Also FDA approved in February 2020, eptinezumab (Vyepti), is an intravenous migraine prophylactic medication manufactured by Lundbeck. In September 2021 the FDA approved Qulipta (atogepant), the first oral CGRP receptor antagonist approved to prevent chronic migraine. [43]

  5. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.

  6. Zavegepant - Wikipedia

    en.wikipedia.org/wiki/Zavegepant

    Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine. [1] Zavegepant is a calcitonin gene-related peptide receptor antagonist. [1]

  7. Ubrogepant - Wikipedia

    en.wikipedia.org/wiki/Ubrogepant

    Ubrogepant, sold under the brand name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.

  8. Erenumab - Wikipedia

    en.wikipedia.org/wiki/Erenumab

    Erenumab was developed by Amgen Inc. in conjunction with Novartis. [5]In the phase III STRIVE clinical trial 955 patients were divided into three groups in a 1:1:1 ratio. Each group was injected subcutaneously monthly with 0, 70 or 140 mg erenumab over a period of 6 months.

  9. Rimegepant - Wikipedia

    en.wikipedia.org/wiki/Rimegepant

    Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic/ preventive treatment of episodic migraine in adults.